Index
Module 10 • Neurology
Neurocritical Care
45%
Data Tables
Neurocritical Care
Keaton S. Smetana ~2 min read Module 10 of 20
24
/ 53

Neurocritical Care

Table 9. Preventive and Abortive Therapies for Paroxysmal Sympathetic Hyperactivity

Preventive Therapies

Abortive Therapies

Baclofen IT (titrated according to patient response)

Bromocriptine 1.25 mg enterally BID (up to 40 mg/day)

Clonidine 0.1–0.3 mg enterally three times daily

Gabapentin 100–300 mg three times daily (up to 4800

mg/day)

Propranolol 20–60 mg enterally every 4–6 hr

Baclofen IT (titrated according to patient response)

Dantrolene 0.25–2 mg/kg IV every 6–12 hr

Dexmedetomidine 0.2–1.5 mcg/kg/hr IVa

Diazepam 5–10 mg IV PRN

Fentanyl 25–100 mcg IV PRN

Morphine 2–8 mg IV PRNa

Propranolol 1–3 mg IV every 4 hra

aMost common treatments.

IT = intrathecal; PRN = as needed.

Rabinstein AA, Benarroch EE. Treatment of paroxysmal sympathetic hyperactivity. Curr Treat Options Neurol 2008;10:151-7; Thomas A, Greenwald BD. Paroxysmal

sympathetic hyperactivity and clinical considerations for patients with acquired brain injuries: a narrative review. Am J Phys Med Rehabil 2019;98:65-72.
VII.ACUTE ISCHEMIC STROKE
A.Epidemiology
1

Fifth leading cause of death and number 1 cause of disability in the United States, with around 800,000

strokes in the United States annually

285% of strokes in the United States are ischemic.
B.Diagnosis/Pathogenesis
1

Diagnostic tests

Neurologic examination

Vital signs

NIH Stroke Scale (greater than 25 is severe, range 1–42)

d.Imaging and other tests (Stroke 2019;50:e344-418)

Noncontrast CT scan or magnetic resonance imaging (MRI) of the brain (to rule out bleeding)

ii.

CT angiography (for patients with evidence of large vessel occlusion)

iii.

CT or MRI perfusion and diffusion imaging may be considered for patients outside the

thrombolysis window.

iv.

Chest radiography (if lung disease is suspected)

Lumbar puncture (if SAH is suspected and CT scan is negative for blood)

vi.

EEG (if seizures are suspected)

2Laboratory tests

Blood glucose

INR, activated partial prothrombin time (consider thrombin time, anti–factor Xa [anti-Xa] activity

for direct oral anticoagulants)

Complete blood cell count (CBC)

d.Tests for hypercoagulable state
C.Causes
1

Cardioembolic (29.1%)

2Large-artery atherosclerosis (16.3%)
3

Lacunar infarcts (15.9%)

HD Video Explanation β€” Synchronized with PDF
Starts at: minute 23 Open on YouTube